Health TrialsbyHealthPanel

Myeloproliferative Neoplasms (MPNs) Patient Registry

ConditionsPrimary MyelofibrosisPolycythemia VeraEssential ThrombocythemiaMastocytosisLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeLeukemia, Myelomonocytic, JuvenileChronic Eosinophilic Leukemia-not Otherwise SpecifiedMyelodysplastic-Myeloproliferative DiseasesNeoplasmsLeukemia, Myelomonocytic, Chronic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Health Network, Toronto

About this trial

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Atypical CML (aCML)

Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),

Chronic myelomonocytic leukemia (CMML)

Chronic neutrophilic leukemia (CNL),

Disqualifiers

None

Trial population

Patients at Princess Margaret Cancer Centre with an MPN diagnosis who consent to inclusion in this registry.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Observational

    Other intervention

Treatment groups

5,000 Participants
are divided into 1 treatment group
Group A: Patients with a diagnosis of MPN1 intervention

Trial outcomes

Primary outcomes

1

Survival

Survival of patients with MPN

Time frame
Annually or at the time of transformation of disease, up to 10 years

Secondary outcomes

1

General patient characteristics will be captured from the Hematologic Malignancy tissue bank

Type and phase of MPN, previous cancer history, age, sex

Time frame
Annually or at the time of transformation of disease, up to 10 years
2

Disease risk score

Risk stratification (IPSS, DIPSS and DIPSS) o Details of transformation to accelerated/phase phase disease

Time frame
Annually or at the time of transformation of disease, up to 10 years
3

Quality of life - Neoplasm Symptom

MPN-SAF TSS questionnaire

Time frame
Annually or at the time of transformation of disease, up to 10 years
4

Co-morbidities

HCT-CI

Time frame
Annually or at the time of transformation of disease, up to 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Health Network, Toronto

Lead sponsor

Source ClinicalTrials.gov
Apply now